Hemorrhagic Fever News and Research

RSS

Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.

Researchers identify new biomarker for severe COVID-19

During the pandemic, it has become increasingly evident that people with cardiovascular disease and obesity are at a much higher risk of developing very severe, even fatal COVID-19 disease.

8 Oct 2021

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

A version of SARS-CoV-2, the virus that causes COVID-19 disease, has been successfully modified to glow brightly in cells and animal tissues, providing a real-time way to track the spread and intensity of viral infection as it happens in animal models, researchers at Texas Biomedical Research Institute report in the journal The Proceedings of the National Academy of Sciences.

27 Sep 2021

Researchers discover how Rift Valley fever virus enters cells

Rift Valley fever virus causes economically devastating outbreaks of hemorrhagic fever in livestock such as sheep, goats and cattle.

24 Sep 2021

Study uncovers the complex cellular mechanisms of Ebola virus

Mount Sinai researchers have uncovered the complex cellular mechanisms of the Ebola virus, which could help explain its severe toll on humans and identify potential pathways to treatment and prevention.

8 Jul 2021

Researchers identify proteins that contribute to the pathogenicity of COVID-19 virus

Researchers at Texas Biomedical Research Institute (Texas Biomed) have narrowed down the proteins enabling SARS-CoV-2 to cause disease.

1 Jul 2021

Could microalgae-derived antiviral compounds combat SARS-CoV-2 and other viruses?

A new review article published in the journal Antibiotics reports the presence of a large number of bioactive compounds in microalgae that target chemical structures present only in their structure.

28 Jun 2021

Texas Biomed scientists receive $1 million NIH funding for Ebola research

Scientists have a general idea of how viruses invade and spread in the body, but the precise mechanisms are actually not well understood, especially when it comes to Ebola virus.

18 Jun 2021

Missing antibody molecule may predict disease severity in secondary dengue infection

A first encounter with the dengue virus typically causes very mild symptoms; however, a subsequent infection is a different story.

5 Jun 2021

Mast cell activation may underlie inflammation in severe COVID-19

A new preprint research paper posted to the medRxiv* server points to mast cells as major culprits in the etiology of severe and critical COVID-19. This could suggest suitable therapeutic and preventive interventions to reduce the morbidity and mortality of this viral illness.

3 Jun 2021

Scientists test antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus

Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected.

2 Jun 2021

Zoonotic and vector-borne emerging tropical diseases pose a constant threat

A recent article published in the journal Frontiers in Tropical Diseases assessed the threat of emerging zoonotic and vector-borne tropical diseases.

26 May 2021

Scientists unveil new Ebola virus vaccine design

Scientists at Scripps Research have unveiled a new Ebola virus vaccine design, which they say has several advantages over standard vaccine approaches for Ebola and related viruses that continue to threaten global health.

13 May 2021

Natural products a rich source for novel antiviral compounds

In a recent review in the journal Viruses, researchers look at natural products that can be identified as potential alternative antiviral agents. The reviewers discussed the antiviral activities of several natural products towards DNA and RNA viruses with an analytical approach. The researchers detailed the cellular/viral targets of the active molecules and their impact on the infection and viral replication cycle.

10 May 2021

Researchers report encouraging results from experimental antiviral targeting Marburg virus

The Marburg virus, a relative of the Ebola virus, causes a serious, often-fatal hemorrhagic fever. Transmitted by the African fruit bat and by direct human-to-human contact, Marburg virus disease currently has no approved vaccine or antivirals to prevent or treat it.

7 May 2021

Broadly neutralizing antibodies show promise in preventing tick-borne encephalitis in mice

Tick-borne encephalitis is a disease just as nasty as it sounds. Once bitten by an infected tick, some people develop flu-like symptoms that resolve quietly but leave behind rampant neurological disease--brain swelling, memory loss, and cognitive decline.

9 Apr 2021

Texas Biomed receives DoD subcontracts to assess SARS-CoV-2 decontamination technologies

Texas Biomedical Research Institute received two Department of Defense's (DoD) Defense Health Agency subcontracts to assess the efficacy of surface coating and aerosolized decontamination technologies to combat SARS-CoV-2 and other respiratory pathogens on surfaces and in the air.

11 Mar 2021

Researchers identify a new drug target for Ebola, Marburg viruses

Ebola and Marburg are among the most deadly viruses, with mortality rates from these infections ranging from 25% to 90%.

8 Feb 2021

Texas Biomed to investigate the effects of cannabinoids on HIV-associated neurocognitive disorder

The National Institutes of Health (NIH) awarded Professor Mahesh Mohan, D.V.M., Ph.D., and collaborators more than $3.5 million over five years to investigate the effects of cannabinoids on Human Immunodeficiency Virus (HIV) associated neurocognitive disorder (HAND).

11 Dec 2020

Experimental vaccine protects cynomolgus macaques against Crimean-Congo hemorrhagic fever virus

An experimental vaccine developed in Europe to prevent infection by Crimean-Congo hemorrhagic fever virus (CCHFV) has protected cynomolgus macaques in a new collaborative study from National Institutes of Health scientists.

30 Nov 2020

Texas Biomed awarded $1 million to evaluate MAb therapeutics for COVID-19

Texas Biomedical Research Institute in San Antonio, Texas, was awarded $1 million from the Bill & Melinda Gates Foundation to test the efficacy of human monoclonal antibodies (MAbs) for the treatment of SARS-CoV-2 infection.

19 Nov 2020